Results 211 to 220 of about 147,176 (269)

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

In-depth 3D exploration of autosomal dominant polycystic kidney disease through light sheet fluorescence microscopy. [PDF]

open access: yesSci Rep
Delgado-Rodriguez P   +10 more
europepmc   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

Synthesis of a Highly Fluorescent Quinoxalino[2,3-<i>b</i>]quinoxaline Polycyclic Derivative via Intramolecular Michael Addition to a Squaramide Ring. [PDF]

open access: yesJ Org Chem
Picci G   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy